Body Central Corp. (BODY) Reaffirms Q2 and FY11 Guidance
Tweet
Share
E-mailGet Alerts BODY Hot Sheet
Join SI Premium – FREE
Body Central Corp. (Nasdaq: BODY) reaffirms its second quarter and FY11 guidance.
Revenue for Q2 is expected to fall between $71 and $73 million while FY11 is estimated to reach $286 to $292 million.
Same-store-sales is forecasted to be in the low teens for Q2 and mid high single digits for the full-year.
Net income for Q2 should be $4.6 to $4.9 million while adjusted EPS is predicted to be between $0.28 and $0.30. Net income for the year will be around $18.3 to $18.9 million with EPS coming in about $1.12 to $1.16.
The company does not anticipate on buying back any shares over the quarter or year, currently has 16.2 million shares outstanding.
Revenue for Q2 is expected to fall between $71 and $73 million while FY11 is estimated to reach $286 to $292 million.
Same-store-sales is forecasted to be in the low teens for Q2 and mid high single digits for the full-year.
Net income for Q2 should be $4.6 to $4.9 million while adjusted EPS is predicted to be between $0.28 and $0.30. Net income for the year will be around $18.3 to $18.9 million with EPS coming in about $1.12 to $1.16.
The company does not anticipate on buying back any shares over the quarter or year, currently has 16.2 million shares outstanding.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- PTC Therapeutics (PTCT) Tops Q1 EPS by 9c, provides guidance
- DexCom (DXCM) Tops Q1 EPS by 5c, provides guidance
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
